ChatGPT Potentially Beneficial for Treating Depression
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Oct. 18, 2023 -- ChatGPT provides recommendations that align with accepted guidelines for management of mild and severe depression, according to a study published online Oct. 4 in Family Medicine and Community Health.
Inbar Levkovich, Ph.D., from Oranim Academic College in Tivon, Israel, and Zohar Elyoseph, Ph.D., from Imperial College London, input vignettes to the ChatGPT interface, focusing mainly on hypothetical patients with symptoms of depression during initial consultations. Eight distinct versions were designed in which patient attributes and depression severities were varied. Each variant was introduced into ChatGPT-3.5 and ChatGPT-4; to ensure consistency and reliability of ChatGPT responses, each vignette was repeated 10 times.
The researchers found that ChatGPT-3.5 and ChatGPT-4 recommended psychotherapy in 95.0 and 97.5 percent of cases, respectively, for mild depression, while primary care physicians recommended psychotherapy in 4.3 percent of cases. For severe cases, primary care physicians mostly recommended "referral for psychotherapy and prescription of pharmacological treatment"; ChatGPT favored this approach more frequently. ChatGPT-3.5 and ChatGPT-4 showed a preference for exclusive use of antidepressants (74 and 68 percent, respectively) in pharmacological recommendations, while primary care physicians generally recommended antidepressants and anxiolytics/hypnotics (67.4 percent). ChatGPT showed no gender or socioeconomic biases in its recommendations, unlike primary care physicians.
"The study suggests that ChatGPT, with its commitment to treatment protocols and absence of biases, has the potential to enhance decision-making in primary health care," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Study Explores Demand for Psilocybin-Assisted Therapy in U.S.
WEDNESDAY, Sept. 18, 2024 -- The demand for psilocybin-assisted therapy (PSIL-AT) for major depressive disorder (MDD) and treatment-resistant depression (TRD) varies from 24 to 62...
Postpartum Anxiety, Depression Not Up After Pandemic Onset, but Benzodiazepine Rx Increased
TUESDAY, Sept. 17, 2024 -- Among privately insured women, diagnoses of postpartum anxiety and depression did not increase following onset of the COVID-19 pandemic, but there was...
Prevalence of Anxiety, Depression Explored in Youth With Chronic Pain
MONDAY, Sept. 16, 2024 -- Among youth with chronic pain, a number of individuals are diagnosed with anxiety and depression when compared with their peers without chronic pain...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.